<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Oxford Biodynamics Plc — News on 6ix</title>
<link>https://6ix.com/company/oxford-biodynamics-plc</link>
<description>Latest news and press releases for Oxford Biodynamics Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 15 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/oxford-biodynamics-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835eaeb78dffbe2df12a6fc.webp</url>
<title>Oxford Biodynamics Plc</title>
<link>https://6ix.com/company/oxford-biodynamics-plc</link>
</image>
<item>
<title>Board Appointment</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/board-appointment-147</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/board-appointment-147</guid>
<pubDate>Wed, 15 Apr 2026 06:00:00 GMT</pubDate>
<description>Oxford BioDynamics Plc announced the appointment of Martin Diggle as a Non-Executive Director, effective April 15, 2026, nominated by its largest shareholder, Vulpes Investment Management. Diggle, co-founder of Vulpes Investment Management and Chairman of the Vulpes Life Sciences fund, brings extensive life sciences and capital markets experience, having served on the boards of several public and private companies. This appointment replaces Stephen Diggle, who stepped down on January 26, 2026.
</description>
</item>
<item>
<title>OBD to present at PMWC 2026</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/obd-to-present-at-pmwc-2026</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/obd-to-present-at-pmwc-2026</guid>
<pubDate>Tue, 03 Mar 2026 09:30:00 GMT</pubDate>
<description>Oxford BioDynamics Plc announced that its Chief Data Officer will present the new EpiSwitch Orion platform at the Precision Medicine World Conference 2026. This platform analyzes the 98% of the genome typically considered "dark matter" to provide real-time clinical insights, bridging the gap between static DNA data and functional disease states. Powered by the EpiSwitch Knowledgebase, which links over 15 million genomic interactions to clinical action using AI, EpiSwitch Orion aims to improve pa</description>
</item>
<item>
<title>Change of Nominated Adviser</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/change-of-nominated-adviser-22</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/change-of-nominated-adviser-22</guid>
<pubDate>Tue, 17 Feb 2026 07:00:00 GMT</pubDate>
<description>Oxford BioDynamics Plc has appointed Singer Capital Markets Advisory LLP as its new Nominated Adviser and Broker, effective immediately. This change in advisory and brokerage services is the primary focus of the announcement.
Disclaimer*</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/holdings-in-company-360</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/holdings-in-company-360</guid>
<pubDate>Tue, 27 Jan 2026 12:52:00 GMT</pubDate>
<description>Sankofa Strategic Equity Fund Ltd has notified Oxford BioDynamics PLC of a change in its major holding, with its total voting rights decreasing from 6.57% to 4.94% as of November 28, 2025. This reduction represents 21,185,5049 voting rights, with no financial instruments contributing to this holding. The notification was made on January 27, 2026.
Disclaimer*</description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/result-of-agm-314</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/result-of-agm-314</guid>
<pubDate>Mon, 26 Jan 2026 12:10:00 GMT</pubDate>
<description>Oxford BioDynamics Plc announced that all resolutions proposed at its Annual General Meeting were passed, with the financial statements and director reports receiving 99.96% approval. However, resolutions concerning the Remuneration Committee report and the re-election of Dr. David Holbrook saw significant opposition, with 37.26% and 37.30% of votes cast against them respectively. The Board acknowledged this shareholder feedback and plans to consult further to understand these concerns. Special </description>
</item>
<item>
<title>Board Change</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/board-change-64</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/board-change-64</guid>
<pubDate>Mon, 26 Jan 2026 07:00:00 GMT</pubDate>
<description>Oxford BioDynamics Plc announced that Stephen Diggle has stepped down as a Director, having served as Non-Executive Director since October 2016. Vulpes Investment Management, controlled by Diggle, remains the company's largest shareholder and will nominate a new non-executive director. The company thanked Diggle for his support and wisdom over his tenure.
Disclaimer*</description>
</item>
<item>
<title>Pilot Study Finds 30-Day Molecular Improvement in Prostate Health Following Intraprostatic Ozone Therapy, Tracked by the EpiSwitch® PSE Blood Test</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/pilot-study-finds-30-day-molecular-improvement-in-prostate-health-following-intraprostatic-ozone-therapy-tracked-by-the-episwitchr-pse-blood-test</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/pilot-study-finds-30-day-molecular-improvement-in-prostate-health-following-intraprostatic-ozone-therapy-tracked-by-the-episwitchr-pse-blood-test</guid>
<pubDate>Thu, 22 Jan 2026 10:00:00 GMT</pubDate>
<description>Doctors Studio by Forum Health, LLC today announced pilot findings indicating that intraprostatic ozone therapy was associated with measurable molecular improvement in prostate health within 30 days, quantified by the EpiSwitch® Prostate Cancer Detection (PSE) blood test. In this 10-patient cohort (ages 54–76), mean PSE probability scores decreased from 0.56 (±0.27) at baseline to 0.39 (±0.31) post-therapy—a relative reduction of approximately 31% (paired t-test, p=0.045; Cohen's d=0.69). Eight</description>
</item>
<item>
<title>Publication of 2025 Annual Report</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/publication-of-2025-annual-report</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/publication-of-2025-annual-report</guid>
<pubDate>Mon, 22 Dec 2025 11:00:00 GMT</pubDate>
<description>Oxford BioDynamics Plc has published its annual report and accounts for the year ended 30 September 2025, making it available on their website and posting hard copies to shareholders. The company, which specializes in precision clinical diagnostics using its EpiSwitch® 3D genomics platform, will hold its Annual General Meeting on 26 January 2026.
Disclaimer*</description>
</item>
<item>
<title>Preliminary Results and Notice of AGM</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/preliminary-results-and-notice-of-agm-3</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/preliminary-results-and-notice-of-agm-3</guid>
<pubDate>Tue, 16 Dec 2025 07:00:00 GMT</pubDate>
<description>Oxford BioDynamics Plc reported total revenue of £1.1 million for the year ended 30 September 2025, a significant increase from £0.6 million in the prior year, driven by clinical test revenue that more than doubled to £1.1 million. The company reduced its operating loss to £11.1 million from £12.9 million in the previous year, while cash and cash equivalents stood at £1.4 million. Post-year end, Oxford BioDynamics successfully raised £7 million to fund ongoing operations, following a £7.35 milli</description>
</item>
<item>
<title>Notice of Results</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/notice-of-results-114</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/notice-of-results-114</guid>
<pubDate>Tue, 09 Dec 2025 12:40:00 GMT</pubDate>
<description>Oxford BioDynamics Plc has announced that it expects to release its results for the year ended 30 September 2025 on Tuesday, 16 December 2025. The company, which specializes in precision clinical diagnostics using its EpiSwitch® 3D genomics platform, currently offers two commercial products: the EpiSwitch® PSE for prostate cancer screening and the EpiSwitch® CiRT for predicting response to immuno-oncology treatments.
Disclaimer*</description>
</item>
<item>
<title>Statement re share price, update on EpiSwitch PSE</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/statement-re-share-price-update-on-episwitch-pse</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/statement-re-share-price-update-on-episwitch-pse</guid>
<pubDate>Wed, 03 Dec 2025 07:00:00 GMT</pubDate>
<description>Oxford BioDynamics Plc has issued a statement addressing recent share price movements, clarifying that the UK National Screening Committee's draft recommendation on prostate cancer screening has no direct impact on the company or its EpiSwitch PSE test. The company highlighted that sales of its PSE test in the US and to private healthcare in the UK have shown consistent growth, with six consecutive record months reported from June to November 2025, indicating ongoing commercial success.
</description>
</item>
<item>
<title>PDMR Dealing / Grant of Share Options</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/pdmr-dealing-grant-of-share-options</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/pdmr-dealing-grant-of-share-options</guid>
<pubDate>Mon, 10 Nov 2025 07:00:00 GMT</pubDate>
<description>Oxford BioDynamics Plc has granted 170,000,000 share options to employees and advisers, including directors, at an exercise price of 0.61 pence per share, a 100% premium to the previous day's closing price. Of these, 119,000,000 options are for directors and PDMRs and will vest monthly over 24 months, while the remaining 51,000,000 options will vest in three tranches with immediate vesting for 20% and further vesting on November 10, 2026, and November 10, 2027, for the rest. The Executive Chairm</description>
</item>
<item>
<title>Result of General Meeting/PDMR Dealings</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/result-of-general-meetingpdmr-dealings</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/result-of-general-meetingpdmr-dealings</guid>
<pubDate>Fri, 07 Nov 2025 11:32:00 GMT</pubDate>
<description>Result of General Meeting/PDMR Dealings.</description>
</item>
<item>
<title>Fundraising, Posting of Circular & Notice of GM</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/fundraising-posting-of-circular-and-notice-of-gm</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/fundraising-posting-of-circular-and-notice-of-gm</guid>
<pubDate>Wed, 22 Oct 2025 06:00:00 GMT</pubDate>
<description>Oxford BioDynamics PLC announced a conditional fundraising to raise £7 million before fees. This will be achieved through a placing of 2,301,666,661 new ordinary shares and direct subscriptions for 31,666,665 new ordinary shares, both at an issue price of £0.003 per share. The new ordinary shares will represent approximately 54.4% of the company's enlarged ordinary share capital. The fundraising is conditional on shareholder approval at a General Meeting on November 7, 2025, and admission of the</description>
</item>
<item>
<title>OBD in New Report on NHS Prostate Cancer Screening</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/obd-in-new-report-on-nhs-prostate-cancer-screening</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/obd-in-new-report-on-nhs-prostate-cancer-screening</guid>
<pubDate>Tue, 14 Oct 2025 06:00:00 GMT</pubDate>
<description>Oxford BioDynamics announced that a Prostate Cancer Research report highlights the potential of its EpiSwitch PSE test within a targeted NHS prostate cancer screening program. The report suggests a national screening program for high-risk men aged 45-69 is feasible and should consider new technologies like EpiSwitch PSE. Modelling indicates that using a reflex test with high specificity and sensitivity could reduce MRI demand by over 86% and biopsy procedures by 84%, while also saving costs. The</description>
</item>
<item>
<title>OBD and UEA develop test for Chronic Fatigue</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/obd-and-uea-develop-test-for-chronic-fatigue</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/obd-and-uea-develop-test-for-chronic-fatigue</guid>
<pubDate>Wed, 08 Oct 2025 06:00:00 GMT</pubDate>
<description>Oxford BioDynamics PLC announced the development of a new blood test for Chronic Fatigue Syndrome (CFS), also known as Myalgic Encephalomyelitis (ME), achieving 96% accuracy. The test demonstrated 92% sensitivity and 98% specificity in identifying the condition. The company aims to identify a partner to co-develop or license the test for clinical use. This breakthrough utilizes OBD's EpiSwitch® 3D genomics biomarker technology to identify unique markers in the blood of ME/CFS patients.
</description>
</item>
<item>
<title>Study confirms clinical utility of EpiSwitch CiRT</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/study-confirms-clinical-utility-of-episwitch-cirt</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/study-confirms-clinical-utility-of-episwitch-cirt</guid>
<pubDate>Thu, 04 Sep 2025 09:00:00 GMT</pubDate>
<description>Oxford BioDynamics announced interim results from its PROWES trial, demonstrating the clinical utility of its EpiSwitch CiRT test. The study, which included 205 patients, showed that CiRT influenced treatment decisions in 61% of cases. CiRT exhibits high sensitivity (93%), specificity (82%), and accuracy (85%) in predicting patient response to immune checkpoint inhibitors. The company plans to apply for inclusion in US National Comprehensive Cancer Network clinical guidelines later this year. Th</description>
</item>
<item>
<title>Collaboration with Google Cloud</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/collaboration-with-google-cloud</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/collaboration-with-google-cloud</guid>
<pubDate>Wed, 13 Aug 2025 06:00:00 GMT</pubDate>
<description>Collaboration with Google Cloud.</description>
</item>
<item>
<title>GenomeWeb to host joint Agilent/OBD presentation</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/genomeweb-to-host-joint-agilentobd-presentation</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/genomeweb-to-host-joint-agilentobd-presentation</guid>
<pubDate>Thu, 17 Jul 2025 06:01:00 GMT</pubDate>
<description>GenomeWeb to host joint Agilent/OBD presentation.</description>
</item>
<item>
<title>Pfizer study on EpiSwitch biomarkers</title>
<link>https://6ix.com/company/oxford-biodynamics-plc/news/pfizer-study-on-episwitch-biomarkers</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biodynamics-plc/news/pfizer-study-on-episwitch-biomarkers</guid>
<pubDate>Tue, 15 Jul 2025 06:00:00 GMT</pubDate>
<description>Pfizer study on EpiSwitch biomarkers.</description>
</item>
</channel>
</rss>